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Pre-hypertension, pre-diabetes or both: which is best at
predicting cardiovascular events in the long term?
A Khosravi1, M Gharipour2, P Nezafati3,4, Z Khosravi5,6, M Sadeghi7, A Khaledifar8, M Taheri8, J Golshahi9 and N Sarrafzadegan9
The present study aimed to assess the value of pre-diabetes and pre-hypertension in predicting cardiovascular events. A
population-based, cross-sectional survey was conducted, representing a large sample of the general Iranian population aged 35
years and older from the Isfahan Province and determined using a random, multistage cluster-sampling 10-year cohort. The ﬁve
end points considered as study outcome were unstable angina (UA), acute occurrence of myocardial infarction (MI), sudden cardiac
death (SCD), brain stroke and cardiovascular disease (CVD). Of the 6323 subjects scheduled for assessment of diabetes state 617
were diabetics and 712 were pre-diabetic. In addition, of these subjects, 1754 had hypertension and 2500 had pre-hypertension.
Analysing only pre-hypertension, pre-diabetes and its combination and adjusted for gender and age variables, pre-hypertension
and pre-diabetes status together, could only effectively predict occurrence of MI (hazard ratio (HR) = 3.21, 95% conﬁdence interval
(CI): 1.06–9.76, P= 0.04). In the same COX regression models, pre-hypertension status could predict UA and CVD occurrence
(HR = 2.94, 95% CI: 1.68–5.14, Po0.001 and HR= 1.74, 95% CI: 1.23–2.47, P= 0.002, respectively). However, pre-diabetes status could
not predict any of these events after adjustment for gender and age. Our data provide valuable evidence of the triggering role of
pre-hypertension and pre-diabetes together, on appearance and progression of MI even in healthy individuals and the signiﬁcant
predicting value of pre-hypertension on the occurrence of UA and CVD. In this regard, the value of pre-hypertension and pre-
diabetes together, and the pre-hypertension state alone, are clearly superior to pre-diabetes state alone in predicting cardiovascular
events.
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INTRODUCTION
Cardiovascular diseases (CVDs) are considered one of the main
causes of mortality and life-threatening morbidity worldwide.1 In
communities with higher prevalence of CVDs, uncontrolled
potential risk factors, such as hypertension and diabetes mellitus,
may lead to higher mortality and morbidity.1 Even a slight change
in blood pressure or insulin resistance has been shown to be
associated with an increased risk of signiﬁcant mortality and
adverse cardiac events in patients from such communities.2 In this
regard, the two clinical conditions of pre-hypertension or pre-
diabetes are not only the precursors to systemic hypertension and
diabetes mellitus but can also increase the susceptibility to
develop coronary atherosclerosis. In this context, the combination
of these two predisposing factors is more likely to lead to severe
coronary artery disease (CAD) than expected with either one
alone.3 According to recent reports regarding the high prevalence
of these two clinically risky conditions in some countries, their
potential role in CVD occurrence should be considered. In two
large surveys in the United States and South Korea, the overall
prevalence of pre-hypertension was 30% of the general
populations.4,5 The prevalence of pre-diabetes has been estimated
in the range of 15.5% in Eastern countries, up to 35% in Western
countries and in Iran it is 13%.6,7 It seems that the prevalence of
these conditions may be higher than the reported ranges because
of the unawareness of the majority of affected individuals of their
risk.8 The underlying pathophysiological causes related to pre-
hypertension and pre-diabetes leading to increased risk of
cardiovascular disorders remain unknown. It has been suggested
that individuals with these clinical conditions have the same risk
factors such as insulin resistance, hypertension, hyperlipidemia,
obesity, low physical activity, endothelial dysfunction, abnormal
coagulative state and inﬂammatory conditions, as those linked to
increased risk of cardiovascular events.9 Despite the demonstrated
role of pre-hypertension and pre-diabetes in possible progress to
hypertension and diabetes mellitus, as well as their status as risk
factors for atherosclerotic events, it has remained unclear which of
these conditions can predict cardiovascular events more effec-
tively. The present study aimed to assess the impact of pre-
diabetes and pre-hypertension, separately and in combination to
predict unstable angina (UA), myocardial infarction (MI), brain
stroke, sudden cardiac death (SCD) and CVD (consisting either of
UA, MI, brain stroke or SCD) in a large longitudinal cohort in Iran.
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MATERIALS AND METHODS
This research was based on a large longitudinal cohort study, begun in
2001. With the use of a randommultistage cluster sampling, a large sample
was originally selected from urban and rural population of 19 years and
older from Isfahan, Najafabad and Arak at the central part of Iran and was
followed for 10 years. The detailed methods, sampling and measurements,
and population characteristics were previously presented.8–12 Patients with
metabolic and inﬂammatory disorders and those administered by any
agents affecting their carbohydrate and lipid metabolisms were excluded
from the study. At the baseline, all the participants were void of CVD or any
kidney disease. Before collecting the data, each participant offered his/her
written informed consent. The research committee at Isfahan Cardiovas-
cular Research Institute as a collaborating centre of WHO approved the
protocol. By the use of a validated questionnaire including demographic
features, socioeconomic information, history of medications and risk
factors for cardiovascular diseases, the trained medical personnel collected
the baseline data. Furthermore, measurements of body weight and height
were done on a calibrated beam scale and wall-mounted stadiometer
barefoot to the nearest 0.1 kg and 0.1 cm, respectively. Then, body weight
(kg) was divided by height (m2) to obtain body mass index. Also, some
questions concerning current smoking and dietary, and lifestyle habits
were asked to identify the presence of any cardiovascular risk factors.
Those involved in regular smoking of a tobacco product once or more
times per day or at any time in the past 30 days were deﬁned as the
smokers in this research;12 hypercholesterolaemia as total cholesterol
⩾ 5.0 mmol l− 1, high-density lipoprotein-cholesterol ⩾ 1.0 mmol l− 1 in
males or ⩾ 1.1 mmol l− 1 in females, and triglycerides ⩾ 2.0 mmol l− 1;13
positive ﬁrst-degree family history of CAD in men and women o55 and 65
years old, respectively;14 hypertension as being on antihypertensive
treatment and/or systolic blood pressure of ⩾ 140 mm Hg and/or diastolic
blood pressure of ⩾ 90 mm Hg;15 and symptoms of diabetes mellitus
associated with at least a plasma glucose concentration of
⩾ 11.1 mmol l− 1, fasting plasma glucose of ⩾ 7.0 mmol/l, or 2 hpp
⩾ 11.1 mmol/l.16 A systolic blood pressure of 120–139 mm Hg and/or a
diastolic blood pressure of 80–89 mm Hg was/were determined as a pre-
hypertension case.3
Fasting blood glucose levels of 100–125 mg dl− 1 as impaired fasting
glucose and/or 2-h postprandial (2 hpp) blood glucose levels of
140–199 mg dl− 1 after a load of 75 g oral glucose as impaired glucose
tolerance were the criteria for pre-diabetes diagnosis according to
American Diabetes Association.17
Occurrences of brain stroke, UA, MI, SCD and CVD within a follow-up
period of 9 years were considered as acute cardiovascular outcomes in this
cohort study. Every 2 years, the participants were asked brieﬂy about any
CVD occurrences through phone calls. All the measurements were
repeated every 5 years. This cohort follow-up procedure is explained in
detail elsewhere.8
The most recently published studies on the prevalence of pre-
hypertension and pre-diabetes in various Middle Eastern countries were
reviewed as well. Surveys on normal populations were considered, and
speciﬁc age groups and communities were excluded from the review.
Chi-square and one-way ANOVA (analysis of variance) tests were
employed to compare the percentages between categorical variables
and across quantitative variables, respectively. Also, univariate and
multiple Cox regression analysis were performed based on statistically
signiﬁcant correlations with cardiovascular events to investigate their
independence as the determinants. Moreover, calculations of HR and CIs of
95% were done and P-values of 0.05 or less were regarded to be
statistically signiﬁcant. SPSS software, version 15.0 (SPSS Inc., Chicago, IL,
USA) was used to conduct all the statistical analyses.
RESULTS
A total of 6323 subjects were studied in 2001, 925 were missing in
the follow-ups and the remaining 5398 were followed for 10 years.
Subjects at baseline underwent fasting blood sugar and 2 hpp
blood sugar assessment, 1754 subjects had hypertension, 2500
subjects were pre-hypertensive, 617 were diabetics, 712 pre-
diabetic and 286 had both pre-hypertension and pre-diabetes.
Comparisons of baseline characteristics between the groups are
presented in Table 1. Both diabetes and pre-diabetes were higher
in females than in males. Diabetics and pre-diabetics were older
and had higher mean body mass index (BMI), and lower
prevalence of current smoking than did non-diabetics. The
comparison of baseline data across different groups of blood
pressure categories (Table 1) showed higher female gender
distribution, higher average age, higher BMI and lower current
smoking in those who suffered hypertension than in the pre-
hypertensive group, whereas no signiﬁcant differences were
revealed in these parameters between normotensive and pre-
hypertensive groups. The participants with pre-hypertension
(6.38%) experienced CVDs more than healthy participants
(3.11%; Figure 1). Also, both MI and sudden cardiac death were
more prevalent in subjects with both pre-hypertension and pre-
diabetes (1.07 and 0.72%, respectively). In Table 2, subjects with
hypertension or diabetes mellitus were not analysed and after
adjustment for gender and age, pre-hypertension status could
effectively predict occurrence of CVD and UA (HR= 1.74, 95% CI:
1.23–2.47, P= 0.002 and HR= 2.94, 95% CI: 1.68–5.14, P=o0.001,
respectively), but did not predict appearance of MI, SCD or brain
stroke. In addition, we found that subjects with the combination
of pre-hypertension and pre-diabetes status are at risk of MI 3.21-
folds more than are other subjects (95% CI: 1.23–2.47, P= 0.04).
The same Cox regression models used showed that pre-diabetes
could not predict any of the CVD events.
A literature review of the most recent studies regarding the
prevalence of pre-hypertension and pre-diabetes on normal
populations in Middle Eastern countries is provided in
Table 1. Baseline characteristics in subgroups of study population
Characteristics Non-diabetic Diabetic Pre-diabetic P-value
Male gender 2521 (50.5) 264 (42.8) 283 (39.7) o0.001
Age, years 49.70± 11.33 56.07± 11.27 53.51± 12.47 o0.001
Body mass index, kg m−2 26.26± 4.37 28.34± 4.57 27.79± 4.72 o0.001
Current smoking 820 (16.4) 68 (11.0) 70 (9.8) o0.001
Receiving anti-hypertension drugs 466 (77.8) 142 (82.6) 125 (82.2) 0.254
Receiving anti-lipidemic drugs 382 (46.1) 143 (54.8) 72 (45.6) 0.042
Characteristics Non-hypertensive Hypertensive Pre-hypertensive P-value
Male gender 996 (48.1) 757 (43.2) 1315 (52.6) o0.001
Age, years 45.92± 9.43 57.44± 11.68 50.07± 11.10 o0.001
Body mass index, kg m−2 25.62± 4.31 27.76± 4.55 26.68± 4.40 o0.001
Current smoking 504 (24.4) 290 (16.5) 543 (21.7) o0.001
Receiving anti-diabetes drugs 46 (64.8) 158 (72.5) 110 (70.1) 0.465
Receiving anti-lipidemic drugs 110 (39.3) 300 (59.3) 187 (40.6) o0.001
Data are shown as number (percentage), or mean± s.d.
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Table 3,18–21 and Table 4,22–28 respectively. The percentage of
individuals with pre-hypertension and pre-diabetes in other
countries in the Middle East ranges from 30 to 54.1 and 13.8%
to 44.2%, respectively. Our report ﬁnds the incidences of pre-
hypertension and pre-diabetes are 46.3 and 11.4%, respectively,
which is comparable with the ﬁndings from other countries in the
region.
DISCUSSION
It has been well demonstrated that patients with diabetes or
hypertension accelerate coronary artery involvement and thus can
aggravate cardiovascular events and related outcomes.29,30 The
present study showed that the combination of pre-hypertension
and pre-diabetes can trigger the progression of MI and have been
identiﬁed as potential risk factors for CVD, though, among pre-
hypertension and pre-diabetes conditions, only the former one
can effectively predict the occurrence of myocardial infarction,
whereas pre-diabetes had no signiﬁcant value for predicting any
of the studied CVD events. In total, both pre-hypertension and
pre-diabetes mellitus had high values for predicting CVD events,
adjusted for baseline confounders.
Although pre-diabetes has been found to be a potential risk
factor for MI (unadjusted for gender and sex), after adjusting these
two baseline variables, the predictive role of pre-diabetes for acute
CVD events was not indicated. It seems that the value of pre-
diabetes for triggering cardiac ischaemic events may be
discrepant in men and women as well as in the young and the
elderly. This means that partial changes in blood glucose may be
successfully tolerable in some gender and age subgroups.
Figure 1. Cardiovascular events in healthy, pre-hypertension, pre-diabetes, and pre-diabetes mellitus and pre-hypertension.
Table 2. Adjusted and non-adjusted HR (95% CI) of developing cardiovascular events according to the presence of pre-hypertension, pre-diabetes or
both
Variable Healthy,
N= 1542
Unadjusted Healthy,
N=1542
Adjusted for sex and age
Pre-HTN, N = 1677 Pre-DM, N=145 Pre-HTN and
Pre-DM, N= 247
Pre-HTN, N= 1677 Pre-DM, N= 145 Pre-HTN and
Pre-DM, N= 247
HR
(95% CI)
P-value HR
(95% CI)
P-value HR
(95% CI)
P-value HR
(95% CI)
P-value HR
(95% CI)
P-value HR
(95% CI)
P-value
MI R 1.79
(0.81,
4.01)
0.15 1.25
(0.16,
9.92)
0.83 3.83
(1.28,
11.46)
0.016 R 1.46
(0.65,
3.28)
0.36 1.28
(0.16,
10.14)
0.81 3.21
(1.06,
9.76)
0.04
Stroke R 0.96
(0.50,
1.83)
0.90 0.59
(0.08,
4.14)
0.61 0.37
(0.05,
2.75)
0.33 R 0.78
(0.41,
1.51)
0.47 0.55
(0.07,
4.14)
0.56 0.28
(0.04,
2.09)
0.21
SCD R 2.68
(0.86,
8.32)
0.09 —a —a 5.09
(1.14,
22.83)
0.03 R 2.03
(0.65,
6.38)
0.23 —a —a 4.01
(0.88,
18.31)
0.07
UA R 3.25
(1.87,
5.65)
o0.001 2.69 (0.9,
8.06)
0.08 1.27
(0.37,
4.37)
0.70 R 2.94
(1.68,
5.14)
o0.001 2.69
(0.90,
8.08)
0.08 1.17
(0.34,
4.02)
0.81
CVD R 2.05
(1.45,
2.89)
o0.001 1.39
(0.59,
3.24)
0.45 1.73
(0.92,
3.26)
0.09 R 1.74
(1.23,
2.47)
0.002 1.37
(0.59,
3.21)
0.47 1.47
(0.77,
2.78)
0.24
Abbreviations: CI, conﬁdence interval; CVD, cardiovascular disease; HR, hazards ratio; MI, myocardial infarction; pre-HTN, pre-hypertension;
pre-DM, pre-diabetes mellitus; R, reference; SCD, sudden cardiac death; UA, unstable angina. aNo pre-DM subject had SCD.
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However, some studies may suggest a continuous relationship
between the developing role of pre-diabetes to diabetes, it can be
also considered a high-risk factor but with lower triggering value
in terms of development of acute ischaemic events.31,32 It is
believed that, like diabetes, pre-diabetes can provoke some
molecular processes that impair the structure and functioning of
blood vessels, leading to arterial inﬂammation and vasoconstric-
tion and thus inducing the beginning of atherosclerosis.33–37 In
addition, both pre-diabetes and diabetes status are commonly
prevalent in CAD patients (diagnosed in 35% and 31% of patients,
Table 3. Literature review reporting pre-hypertension prevalence in the Middle Eastern countries
Country Year Author Total
sample
Age
range
mean
Study design Diagnostic
criteria
Finding Conclusion
Iran (This Study) 2016 Khosravi
et al.
5398 35o Cohort JNC 7 Pre-HTN= 46.3%,
HTN= 32.5%
Pre-HTN and Pre-DM together & Pre-HTN
state alone, are superior to Pre-DM in
predicting cardiovascular events
Egypt 2012 El-Din
et al.18
5534 20–75 Cross-sectional JNC 7 Pre-HTN= 49.2%,
HTN= 16.8%
Overweight/obesity and diabetes are risk
factor for HTN. Public awareness
strategies for HTN is needed
Turkey 2010 Gupta
et al.19
10380 20o Cross-sectional JNC 7 Pre-HTN= 36.3%,
HTN= 11.8%
Detection of Pre-HTN, during annual
health maintenance in disease-free
adults, could become an early marker of
adverse cardiometabolic risk proﬁle
Lebanon 2015 Matar
et al.20
1685 20o Cross-sectional JNC 7 Pre-HTN= 30%,
HTN= 37%
Awareness, treatment, and control rates
remain low and should be substantially
improved
Oman 2008 Ganguly
et al.21
327 18o Cross-sectional JNC 7 Pre-HTN= 54.1%,
HTN= 24.2%
In Pre-DM subjects, male gender,
increasing dysglycemia and BMI are the
major determinant for Pre-HTN
Abbreviations: BMI, body mass index; JNC 7, Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure; pre-HTN,
pre-hypertension. Deﬁnition based on JNC 7: systolic blood pressure ranging from 120 to 139 mmHg and/or a diastolic blood pressure ranging from 80 to
89 mmHg
Table 4. Literature review reporting pre-diabetes prevalence in the Middle Eastern countries
Country Year Author Total
sample
Age
range
mean
Study design Diagnostic
criteria
Finding Conclusion
Iran (This Study) 2016 Khosravi et al. 5398 35o Cohort IFG, IGT Pre-DM= 11.4%,
DM= 13.2%
Pre-HTN and pre-DM together
& pre-HTN state alone, are superior to
pre-DM in predicting Cardiovascular
events
Turkey 2013 Satman et al.22 26 499 20o Cross-sectional IFG, IGT Pre-DM= 30.8%,
DM= 16.5%
This ﬁgure is alarming and underscore
the urgent need for national programs
to prevent diabetes, to manage the
illness and thus prevent complications
Iraq 2015 Al-Azzawi et al.23 300 30– 75 Cross-sectional IFG, IGT Pre-DM= 33.7% Pre-DM is associated with Metabolic
syndrome, increasing the burden on
public health care that needs to be
addresses globally
Saudi Arabia 2014 Al-Rubeaan et al.24 53 370 18o Cohort IFG Pre-DM= 22.6%,
DM= 11.9%
Abnormal glucose metabolism has
reached an epidemic state. An urgent
strategy for launching diabetes primary
prevention programs is needed
Lebanon 2014 Ghassibe-Sabbagh et al.25 998 65 Cross-sectional HbA1C Pre-DM= 20.7%,
DM= 40.8%
hypertension, hyperlipidemia, and low
levels of HDL-C are associated with an
increased risk of pre-diabetes and DM.
There is an alarming prevalence of pre-
diabetes and diabetes
Oman 2011 Al-Shafaee et al.26 1313 18– 60 Cross-sectional IFG, IGT Pre-DM= 44.2% Customised interventions targeting
groups with high risk of pre-diabetes,
especially men, the elderly and the
obese, are urgently needed
Kuwait 2016 Zhang et al.27 960 20o Cross-sectional FBG,
HbA1C
Pre-DM= 40%,
DM= 27%
Improving vitamin D status, even to a
small extent, can potentially have a
large impact on diabetes prevention in
this high-risk population
Qatar 2009 Bener A. et al.28 1117 20o Cross-sectional IFG, IGT Pre-DM= 13.8%,
DM= 16.7%
Early diagnosis of DM is of major
importance to reduce the risk of these
diabetes-related conditions
Abbreviations: DM, diabetes mellitus; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; pre-DM, pre-diabetes mellitus; pre-HTN, pre-hypertension.
DM: fasting glucose ⩾ 7.0 mmol l− 1 or, HbA1C ⩾ 6.5 % or, plasma glucose concentration ⩾ 11.1 mmol l− 1 or, fasting blood glucose ⩾ 126 mg dl, or use of
medications to control diabetes. Deﬁnition of Pre-DM used in studies based on: IFG—fasting blood glucose levels from 100 to 125 mg dl−1; IGT—140 to
199 mg dl−1 after a 75 g oral glucose load; HbA1C—5.7–6.4%; fasting blood glucose—5.6 to 6.9 mmol l−1.
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respectively).38 In addition, 460% of individuals with previously
undiagnosed pre-diabetes or diabetes experience myocardial
infarction or undergo coronary catheterization and angiography
following suspected coronary involvement.38 Moreover, a strong
relationship between pre-diabetes status and two traditional
coronary risk factors of obesity and hyperlipidemia has been
suggested.39–41 Individuals with pre-diabetes develop obesity and
dyslipidemia, and thus any assessment of a patient with pre-
diabetes should consist of the measurement of lipid proﬁle as well
as anthropometric parameters, with the aim of CAD risk
stratiﬁcation. However, our results show that pre-diabetes could
not effectively predict the occurrence of any cardiovascular
events. In our study, the insigniﬁcant association between pre-
diabetes and increased risk of cardiovascular events may be due
to the fact that less than half of our pre-diabetic subjects (45.6%),
were under anti-lipidemic drugs and their average BMI
(27.79 = overweight), was not classiﬁed as obese. In addition, the
slight coronary microvascular dysfunction in the patients studied
could be the reason why pre-diabetes could not underlie
ischaemic events. In sum, pre-diabetes remains a matter of
controversy, especially with regard to its management and
treatment in healthy individuals.
Some studies may suggest a continuous relationship between
systolic blood pressure and the progression rate of coronary
atherosclerosis over a broad range of blood pressures extending
from 100 mm Hg to the hypertensive range.42 In this regard, it has
been shown that patients who improved from a pre-hypertensive
state at baseline to normal blood pressure levels had signiﬁcantly
less progression of an atheroma than did patients who remained
pre-hypertensive.43 It has been revealed that the alteration of
coronary ﬂow reserve is signiﬁcantly impaired in patients with pre-
hypertension compared with normotensive subjects; however, in
subjects with pre-hypertension, impairment of coronary ﬂow
reserve was not as severe as in those with hypertension.44 In our
study, the signiﬁcant association between pre-hypertension and
increased risk of cardiovascular events may be due to great
coronary microvascular dysfunction in the patients studied.
Therefore, it is reasonable to consider individuals with pre-
hypertension to be at high risk for UA and CVD, and thus
candidates for coronary diagnostic interventions to reduce the
occurrence of acute ischaemic events in pre-hypertensive patients.
To the best of our knowledge, this is the ﬁrst study in its ﬁeld
among the Middle Eastern countries. Moreover, many Middle
Eastern countries lack sufﬁcient data regarding the prevalence of
pre-hypertension and pre-diabetes. However, as in Table 3,18–21
and Table 4,22–28 the prevalence of pre-hypertension and pre-
diabetes of other countries in the region is relatively comparable
to that found in Iran, considering the growing rate of this
incidence in these regions.
Despite the diversity and inequalities found in Middle Eastern
countries, they still have several health issues in common. This is
possibly related to their relatively similar cultural backgrounds,
socioeconomic circumstances and religion, which result in similar
lifestyles with speciﬁc and preventable known risk factors. The
Middle East is predicted to be among the regions that will
experience a tripling of Coronary heart disease and stroke
mortality over the next two decades.45 Therefore, based on this
study, Middle Eastern countries should consider pre-hypertension
in particular as a strong risk factor for cardiovascular events.
LIMITATION
The fact that our sample was Iranians limits the generalisability of
our ﬁndings beyond the Middle East region. Also, no similar study
could be found in the Middle East, so we were unable to compare
our results with other Middle Eastern countries. In the literature
review on the prevalence of pre-hypertension and pre-diabetes,
only a certain number of countries studied the incidence of these
two factors in their nations, resulting in a limited number of
possible comparisons. In addition, some of the factors such as
subfractions of cholesterol, smoking status, anti-hypertension
drugs, anti-diabetes drugs and anti-lipidemic drugs were not
adjusted in the model in this study.
In conclusion, our data provide valuable evidence of the
triggering role for the combination of pre-hypertension and pre-
diabetes in predicting myocardial infarction, and pre-hypertension
in the occurrence of unstable angina and cardiovascular diseases
even in apparently healthy individuals. In this regard, the value of
pre-hypertension for predicting cardiovascular events is clearly
superior to pre-diabetes state and thus the presence of mildly
elevated blood pressure should be considered seriously by
clinicians or health professionals while planning for preventive
or screening programs.
What is known about topic?
● Cardiovascular diseases (CVDs) are considered one of the main
causes of mortality and life-threatening morbidity worldwide
● Despite the demonstrated role of pre-hypertension and pre-
diabetes in possible progress to hypertension and diabetes
mellitus, as well as their status as risk factors for CVDs, it has
remained unclear, which of these conditions can predict cardio-
vascular events more effectively.
What this study adds?
● There is a valuable evidence of the triggering role for the
combination of pre-hypertension and pre-diabetes in predicting
myocardial infarction which is 3.21-folds more than other subjects,
and pre-hypertension in the occurrence of unstable angina and
cardiovascular diseases even in apparently healthy individuals.
● The value of pre-hypertension for predicting cardiovascular events
is clearly superior to pre-diabetes state and thus the presence of
mildly elevated blood pressure should be considered seriously by
clinicians or health professionals while planning for preventive or
screening programs.
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